Press "Enter" to skip to content

Migraine Patients Have A New Therapy To Help Them Deal With Pain

Researchers have come up with a new drug to treat migraines and it is found to be promising in the clinical trials. The people have their hopes raised high after the reports of the new drug option came up. The drug, ubrogepant, has helped reduce pain and other symptoms in almost 20% of the migraine patients. The drug is found to get active within 2 Hours and help patients deal with light and noise sensitivity. This new medication could help treat acute migraine that has been affecting millions across the globe. According to Dr. Richard B. Lipton from the Montefiore Headache Center in New York, ubrogepant is a drug that has not yet been approved by the US Food and Drug Administration.

Around 40 Million Americans and 1 Billion people from the other regions have been found to be dealing with migraines. The American Migraine Foundation has found the condition to persist 1 in 5 women and 1 in 16 men. Migraine shows symptoms like severe headache on one side of the brain; nausea; noise, smell, & light sensitivity; and vomiting. Some people experience visual disturbances in case of migraines. The condition is found to make a person disable and there is an urgent need for effective and safe treatment. Few patients are given ibuprofen, acetaminophen, or aspirin to deal with migraine. These triptans are considered to be unsafe as the chances of stroke and cardiovascular disease are high. The new drug is found to target calcitonin gene-related peptide (CGRP), a protein that deals with pain. The people having heart problems can consume it as the blood vessels are not targeted. The drug is considered to be a potential option for migraine patients.

In a similar note, a study conducted by Teva Pharmaceuticals proved fremanezumab to be effective and well-tolerated in migraine patients who have found other preventive treatments ineffective. The drug was found to be helping patients deal with extreme headaches. Thus, the hunt for a tolerant and highly effective drug is still being researched.

Ellen McFadden
Author Details
EDITOR-IN-CHIEF At Healthcare Industry Reports

Ellen has been working with the Healthcare Industry Reports portal from the past 6 years and is still going strong. Ellen’s hard work and error-free writing is the reason behind Healthcare Industry Reports handing over the complete responsibility of handling the Healthcare and Services domain. She plans to still add on more credits to her qualification by doing certain writing-based courses. Her vast knowledge on the healthcare field has only helped her write some of the best medical-based contents. The skillful composing of text is a strategy that Ellen has well learned over the years and has it implemented in every text penned down.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *